Pharmena (WAR:PHR) E10: zł-0.57 (As of Mar. 2026)


WAR:PHR Pharmena SA WAR:PHR
56 GF Score
Price zł3.08
GF Value zł5.78
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Pharmena E10?

Pharmena WAR:PHR -3.14% 56 E10 is zł-0.57 as of Mar. 2026. GuruFocus rates WAR:PHR with a GF Score™ of 56/100 and a GF Value™ of zł5.78 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Pharmena's adjusted earnings per share data for the three months ended in Mar. 2026 was zł-0.040. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is zł-0.57 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Pharmena was -5.70% per year. The lowest was -8.30% per year. And the median was -7.00% per year.

As of today (2026-06-29), Pharmena's current stock price is zł3.08. Pharmena's E10 for the quarter that ended in Mar. 2026 was zł-0.57. Pharmena's Shiller PE Ratio of today is .


Pharmena  (WAR:PHR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Pharmena E10 Related Terms


Pharmena E10 Historical Data

* Premium members only.

The historical data trend for Pharmena's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmena E10 Chart

Pharmena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 -0.50 -0.64 -0.61 -0.59

Pharmena Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.61 -0.61 -0.59 -0.57

WAR:PHR vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Pharmena's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmena Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmena's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharmena's Shiller PE Ratio falls into.


WAR:PHR
56GF Score
Pharmena SA WAR:PHR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmena E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharmena's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.04/158.3232*158.3232
=-0.040

Current CPI (Mar. 2026) = 158.3232.

Pharmena Quarterly Data

per share eps CPI Adj_EPS
201606 -0.024 99.552 -0.038
201609 0.004 99.064 0.006
201612 -0.012 100.366 -0.019
201703 -0.068 101.018 -0.107
201706 -0.101 101.180 -0.158
201709 -0.035 101.343 -0.055
201712 -0.063 102.564 -0.097
201803 0.080 102.564 0.123
201806 -0.030 103.378 -0.046
201809 0.030 103.378 0.046
201812 -0.120 103.785 -0.183
201903 -0.060 104.274 -0.091
201906 -0.590 105.983 -0.881
201909 -0.100 105.983 -0.149
201912 -0.210 107.123 -0.310
202003 -0.070 109.076 -0.102
202006 -0.150 109.402 -0.217
202009 -0.070 109.320 -0.101
202012 -0.320 109.565 -0.462
202103 -0.050 112.658 -0.070
202106 -0.170 113.960 -0.236
202109 -0.060 115.588 -0.082
202112 -0.130 119.088 -0.173
202203 -0.020 125.031 -0.025
202206 -0.050 131.705 -0.060
202209 -0.010 135.531 -0.012
202212 -0.070 139.113 -0.080
202303 -0.010 145.950 -0.011
202306 -0.060 147.009 -0.065
202309 2.710 146.113 2.936
202312 -4.240 147.741 -4.544
202403 0.020 149.044 0.021
202406 -0.050 150.997 -0.052
202409 -0.050 153.439 -0.052
202412 -0.030 154.660 -0.031
202503 -0.040 157.021 -0.040
202506 -0.070 157.509 -0.070
202509 -0.060 157.998 -0.060
202512 -0.080 158.323 -0.080
202603 -0.040 158.323 -0.040

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of zł-0.57 mean?
Pharmena (WAR:PHR) has a E10 of zł-0.57 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Pharmena and its competitors.
Is Pharmena's E10 too high?
Pharmena's current E10 is zł-0.57. Overall, Pharmena has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmena's E10 compare to VRTX and REGN?
Pharmena's E10 of zł-0.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Pharmena and its competitors. Pharmena's current E10 is zł-0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmena stock overvalued right now?
Based on GuruFocus' analysis, Pharmena (WAR:PHR) is currently considered Possible Value Trap. The stock's GF Value™ is zł5.78, compared to a current price of zł3.08 — trading 46.7% below its estimated fair value. The current E10 is zł-0.57. Pharmena's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Pharmena (WAR:PHR), the current E10 is zł-0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmena (WAR:PHR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmena stock appears to be undervalued. The current stock price of zł3.08 is trading 46.7% below its estimated GF Value™ of zł5.78. GuruFocus considers Pharmena to be Possible Value Trap.

Key valuation signals for WAR:PHR:

  • E10: zł-0.57
  • GF Value™: zł5.78 vs. price of zł3.08 (46.7% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmena Business Description

Address Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
56GF Score

Get the complete analysis for WAR:PHR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł3.08
Price
zł5.78
GF Value